Table 1 The potential drug resistance driver genes.

AQP3

5.9

−1.86

chr9:36166020–2,725

−70

Regulates cell migration in EGF dependent manner¹⁸

CTSB

5.09

−1.84

chr8:10897405–803

−50

Unfavorable marker for survival¹⁹

CYP24A1

259.33

−2.18

chr20:52556813–213

−67

Increased expression^{20, 21}

PRSS56

−2.94

−2.38

chr2:232290776–1,094

−57

—

ECEL1

−3.46

−2.06

chr2:232290776 1,054

−57

Chemotherapy-resistance²²

SPOCK1

−3.29

−2.65

chr5:133477187 2,834

−54

Growth and metastasis²³

SYNE1

−2.17

−2.22

chr6:156200288–3,242

−71

Mutations predictive for malignant transformation^{24, 25}

PBX1

−2.09

−1.97

chr1:164500920–28

−46

Mediated survival in response to Notch3²⁶

PTGDS

−3.79

−2.08

chr9:136310987 168

68

Chemoresistance³³

ST3GAL5

−2.41

−2.02

chr2:85892782 173

−37.61

Decreased expression²⁷

FOSL1

1.98

1.98

chr11:65682138–14

−43

ER-dependent induction impaired in response to saracatinib+/− fulvestrant²⁸

IL8/CXCL8

1.74

2.14

chr4:68449172–6,157

−44

Chemoresistance³³

ARRDC4

1.95

2.1

chr15:98937633 421

47

—

TNFAIP3

3.33

2.46

chr:136929632–1,259

−63

Induced by ARID3B²⁹

ODC1

2.05

1.94

chr2:10445016 136

−65

Downregulated in response to platinium drugs³⁰

RNF43

3.63

1.66

chr17:55185542 1,245

−34

Tumor supressor and mutation hotspot^{51, 52}

HERC5

2.41

1.74

chr4:68449172–20,929

−44

—

OASL

4.99

1.93

chr12:121177842 280

−56

Chemoresistance³³

KLF4

5.21

2.28

chr9:115618930–5,367

−48

Downregulated and regulates BCL2/Bax ratio⁵³, mediates EMT⁵⁴

IL6

16.27

1.8

chr7:30737735–7,971

−47

Chemoresistance³³, potential prognostic marker^{32, 34}